Group 1 - The core point of the article is that Sangfor Pharmaceutical's dual-specific antibody (code: 707) has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting first-line treatment for PD-L1 positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [1][2] - Lung cancer has the highest incidence and mortality rates among all cancers, with non-small cell lung cancer accounting for approximately 80%-85% of all lung cancer cases [1] - Current treatments for NSCLC, including anti-PD-1/L1 monotherapy and combination chemotherapy, show limited effectiveness, with a 5-year survival rate of only 17%-30% [1] Group 2 - The dual-specific antibody 707 is developed based on the CLF2 patent platform and can simultaneously inhibit VEGF and PD-1, showing significant anti-tumor activity and good safety profile in clinical trials [1] - Sangfor Pharmaceutical is also advancing clinical research for 707 in other cancers such as colorectal cancer, endometrial cancer, and ovarian cancer, and has received FDA IND approval for 707 [2] - The company has partnered with BaiLi Tianheng to explore the potential of 707 in combination with BL-B01D1 for solid tumors in China, enhancing the application prospects of 707 [2]
三生制药抗VEGF/PD-1双特异性抗体707被纳入突破性治疗品种